A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C
Author:
Publisher
Wiley
Subject
Pharmacology (medical),Gastroenterology,Hepatology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1365-2036.2003.01453.x/fullpdf
Reference25 articles.
1. Randomised trial of interferon α2b plus ribavirin for 48 weeks or 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus;Poynard;Lancet,1998
2. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C;McHutchison;N Engl J Med,1998
3. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C;Lindsay;Hepatology,2001
4. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C. A randomised trial;Manns;Lancet,2001
5. International Consensus Conference on Hepatitis C;European Association for the Study of the Liver;J Hepatol,1999
Cited by 58 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Cost–Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong;Digestive Diseases and Sciences;2020-05-08
2. Epidemiology of hepatitis C virus infection in a country with universal access to direct‐acting antiviral agents: Data for designing a cost‐effective elimination policy in Spain;Journal of Viral Hepatitis;2019-12-06
3. Cost-Utility of Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1 Infection;Value in Health;2017-09
4. Chronic Hepatitis C-Related Cirrhosis Hospitalization Cost Analysis in Bulgaria;Frontiers in Medicine;2017-08-07
5. Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response;PLOS ONE;2017-01-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3